Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes

89Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aims/hypothesis. Inflammation could play a part in insulin resistance. Thiazolidinediones, new antidiabetic drugs, possess anti-inflammatory effects in vitro. We investigated if acute-phase serum proteins are increased in patients with Type II (non-insulin-+dependent) diabetes mellitus who had been treated with insulin and whether troglitazone has anti-inflammatory effects in vivo. Methods. A total of 27 patients (age 63.0 ± 1.7 years, HbA(1c) 8.8 ± 0.3%, BMI 32.7 ± 0.8 kg/m2, duration 15.2 ± 1.4 years, insulin dose 73.3 ± 7.0 U/day) participated in the study. The patients received daily either 400 mg troglitazone or placebo for 16 weeks. Blood samples were taken at baseline, at the end of therapy and after a follow-up time of 23 ± 4 days. Results. The concentrations of serum amyloid A (6.2 ± 1.1 mg/1) and C- reactive protein (6.1 ± 1.1 mg/l) were increased (p < 0.001) and complement protein C3 (1.69 ± 0.05 g/l) was also above the reference range for healthy subjects. Placebo treatment had no effect on glucose or inflammation, whereas troglitazone reduced fasting glucose (from 10.4 ± 0.6 mmol/l to 8.1 ± 0.5 mmol/l, p < 0.01), HbA(1c) (from 8.7 ± 0.3 % to 7.5 ± 0.3 %, p < 0.01), insulin requirements (from 75 ± 10 U/day to 63 ± 10 U/day, p < 0.05), serum amyloid A (from 6.3 ± 1.5 mg/l to 4.0 ± 1.3 mg/l, p = 0.001), α-1-acid glycoprotein (from 906 ± 51 mg/l to 729 ± 52 mg/l, p = 0.001) and C3 (from 1.72 ± 0.07 g/l to 1.66 ± 0.06 g/l, p < 0.05) but not α-1-antitrypsin, ceruloplasmin, C-reactive protein or haptoglobin significantly. Concentrations of glucose and acute-phase reactants had returned to those before treatment at the follow-up visit. Conclusion/interpretation. In Type II diabetic patients serum amyloid A and complement protein C3 are raised. Troglitazone exerts a selective reversible action on some acute-phase proteins and C3 but not on others in conjunction with the improvement in glucose metabolism.

Cite

CITATION STYLE

APA

Ebeling, P., Teppo, A. M., Koistinen, H. A., Viikari, J., Rönnemaa, T., Nissén, M., … Koivisto, V. A. (1999). Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes. Diabetologia, 42(12), 1433–1438. https://doi.org/10.1007/s001250051315

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free